Mankind Pharma Limited
NSE: MANKIND BSE: MANKIND
NSE
2,588.40
6.80 (0.26%)
Prev Close
2581.6
Open Price
2586.3
Volume
342,053
Today Low / High
2554.5 / 2609.2
52 WK Low / High
1901.05 / 3054.8
Range
2,459 - 2,718
BSE
2,583.55
0.90 (0.03%)
Prev Close
2582.65
Open Price
2590
Volume
12,659
Today Low / High
2553.1 / 2608
52 WK Low / High
1910.1 / 3050
Range
2,454 - 2,713
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2588.4 (target range: 2,459 - 2,718), reflecting a change of 6.8 (0.2634%). On the BSE, it is listed at 2583.55 (target range: 2,454 - 2,713), showing a change of 0.9 (0.03484793%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
2,586.30
0.08%
17 Apr
2,509.90
2.86%
16 Apr
2,425.00
3.92%
15 Apr
2,420.00
0.25%
11 Apr
2,369.00
-0.78%
09 Apr
2,337.00
-0.99%
08 Apr
2,408.85
-2.55%
07 Apr
2,362.00
0.91%
04 Apr
2,429.00
0.91%
03 Apr
2,463.00
-1.43%
02 Apr
2,458.10
-1.47%
01 Apr
2,423.50
1.43%
28 Mar
2,467.95
-1.75%
27 Mar
2,402.75
2.06%
26 Mar
2,415.00
-0.47%
25 Mar
2,377.00
0.89%
24 Mar
2,423.55
-2.12%
Mankind Pharma Limited Graph
Mankind Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Mankind Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,588.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,583.55 | 2,609.39 | 2,348.45 - 2,870.32 |
| 2,635.22 | 2,108.18 - 3,162.27 | ||
| 2,661.06 | 1,862.74 - 3,459.37 | ||
| Bearish Scenario | 2,583.55 | 2,557.71 | 2,301.94 - 2,813.49 |
| 2,531.88 | 2,025.50 - 3,038.25 | ||
| 2,506.04 | 1,754.23 - 3,257.86 |
Overview of Mankind Pharma Limited
ISIN
INE634S01028
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
635,117
Market Cap
1,067,918,241,168
Last Dividend
0
Official Website
IPO Date
2023-05-09
DCF Diff
1,804.86
DCF
784
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 10,334.77 Cr | 3,320.72 Cr | 7,014.05 Cr | 0.6787 | 25.45 Cr | 2,297.94 Cr | 4,086.76 Cr | 1,912.90 Cr | 47.75 | 2,809.47 Cr | 0.1851 |
| 2023-03-31 | 8,742.85 Cr | 5,354.49 Cr | 3,388.36 Cr | 0.3876 | 188.17 Cr | 1,095.09 Cr | 1,617.98 Cr | 1,281.86 Cr | 32.00 | 2,026.67 Cr | 0.1466 |
| 2022-03-31 | 7,781.56 Cr | 2,470.01 Cr | 5,311.55 Cr | 0.6826 | 213.45 Cr | 124.69 Cr | 1,923.33 Cr | 1,433.48 Cr | 35.78 | 2,146.95 Cr | 0.1842 |
| 2021-03-31 | 6,214.43 Cr | 1,824.98 Cr | 4,389.45 Cr | 0.7063 | 170.79 Cr | 74.88 Cr | 1,665.53 Cr | 1,265.43 Cr | 31.59 | 1,816.57 Cr | 0.2036 |
| 2020-03-31 | 5,865.23 Cr | 1,923.37 Cr | 3,941.87 Cr | 0.6721 | 0.00 Cr | 52.97 Cr | 1,513.86 Cr | 1,030.43 Cr | 25.72 | 1,540.89 Cr | 0.1757 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 382.01 Cr | 11,963.25 Cr | 2,387.47 Cr | 9,363.0881 Cr | 207.17 Cr | -174.84 Cr | 1,553.46 Cr | 3,138.69 Cr | 49.75 Cr | 22.96 Cr | -407.07 Cr | 2,119.7298 Cr |
| 2023-03-31 | 304.82 Cr | 9,715.45 Cr | 2,066.66 Cr | 7,435.2228 Cr | 170.37 Cr | -134.45 Cr | 1,528.85 Cr | 3,075.80 Cr | 26.37 Cr | 25.49 Cr | 372.45 Cr | 1,863.1362 Cr |
| 2022-03-31 | 302.53 Cr | 9,147.74 Cr | 2,831.43 Cr | 6,155.2290 Cr | 873.08 Cr | 570.54 Cr | 1,760.24 Cr | 2,389.59 Cr | 520.46 Cr | 20.15 Cr | -736.38 Cr | 2,623.4690 Cr |
| 2021-03-31 | 167.18 Cr | 6,372.63 Cr | 1,509.74 Cr | 4,722.0020 Cr | 240.66 Cr | 73.48 Cr | 1,183.54 Cr | 1,991.69 Cr | 422.78 Cr | 7.89 Cr | -1,627.56 Cr | 1,353.3980 Cr |
| 2020-03-31 | 226.08 Cr | 5,073.29 Cr | 1,401.72 Cr | 3,485.3090 Cr | 130.88 Cr | -95.19 Cr | 899.14 Cr | 1,864.60 Cr | 380.61 Cr | 17.79 Cr | -693.88 Cr | 1,258.5890 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 2,152.4450 Cr | -2,081.6903 Cr | 5.2656 Cr | 1,770.1082 Cr | 77.1868 Cr | 382.0075 Cr | -389.2112 Cr | 1,912.8967 Cr | 33.9638 Cr | 0.0000 Cr | -55.0030 Cr |
| 2023-03-31 | 1,784.5862 Cr | -1,066.8951 Cr | -698.2462 Cr | 952.5172 Cr | 2.2867 Cr | 304.8207 Cr | -832.0690 Cr | 1,281.8591 Cr | -695.2432 Cr | 0.0000 Cr | 261.7799 Cr |
| 2022-03-31 | 919.7760 Cr | -1,369.1430 Cr | 604.6200 Cr | -1,425.7470 Cr | 155.7310 Cr | 283.0590 Cr | -2,345.5230 Cr | 1,974.5990 Cr | -4.5695 Cr | 0.0000 Cr | -576.7000 Cr |
| 2021-03-31 | 1,137.2440 Cr | -1,222.2110 Cr | -7.8110 Cr | 824.9280 Cr | -92.4030 Cr | 127.3280 Cr | -312.3160 Cr | 1,691.6110 Cr | 0.2670 Cr | 0.0000 Cr | -284.4030 Cr |
| 2020-03-31 | 1,069.7050 Cr | -439.1550 Cr | -530.7380 Cr | 841.7350 Cr | 103.4160 Cr | 219.7310 Cr | -227.9700 Cr | 1,437.7350 Cr | -139.6620 Cr | -364.2660 Cr | -78.1490 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 3,230.00 Cr | 935.22 Cr | 2,294.78 Cr | 0.7105 | 637.50 Cr | 380.23 Cr | 9.45 | 910.56 Cr | 0.1177 |
| 2024-09-30 | 3,076.51 Cr | 1,626.94 Cr | 1,449.57 Cr | 0.4712 | 744.42 Cr | 653.47 Cr | 16.31 | 962.04 Cr | 0.2124 |
| 2024-06-30 | 2,893.42 Cr | 1,554.05 Cr | 1,339.37 Cr | 0.4629 | 574.02 Cr | 536.49 Cr | 13.39 | 782.36 Cr | 0.1854 |
| 2024-03-31 | 2,441.10 Cr | 737.29 Cr | 1,703.81 Cr | 0.6980 | 580.96 Cr | 471.24 Cr | 11.76 | 683.23 Cr | 0.1930 |
| 2023-12-31 | 2,606.96 Cr | 827.59 Cr | 1,779.37 Cr | 0.6825 | 571.51 Cr | 453.76 Cr | 11.33 | 676.64 Cr | 0.1741 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 1,192.58 Cr | 3,534.16 Cr | 4,726.74 Cr | 1,275.42 Cr | 1,678.85 Cr | 8,536.75 Cr | 3,140.48 Cr | 13,982.25 Cr | 3,192.95 Cr |
| 2024-06-30 | -3,386.50 Cr | 6,772.99 Cr | 3,386.50 Cr | 0.00 Cr | 0.00 Cr | 3,386.50 Cr | 0.00 Cr | 0.00 Cr | -9,575.79 Cr |
| 2024-03-31 | 382.01 Cr | 3,087.24 Cr | 3,469.24 Cr | 896.87 Cr | 1,553.46 Cr | 6,568.23 Cr | 3,138.69 Cr | 11,963.25 Cr | 2,387.47 Cr |
| 2023-12-31 | -2,325.90 Cr | 4,651.79 Cr | 2,325.90 Cr | 0.00 Cr | 0.00 Cr | 2,325.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 253.49 Cr | 2,098.42 Cr | 2,351.90 Cr | 1,057.20 Cr | 1,533.79 Cr | 5,662.32 Cr | 3,100.54 Cr | 11,098.32 Cr | 2,464.73 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 536.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 471.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 453.76 Cr | 219.45 Cr | 0.00 Cr | 0.00 Cr | 219.45 Cr | 472.94 Cr | 253.49 Cr | 0.00 Cr | 219.45 Cr |
| 2023-09-30 | 501.03 Cr | 192.97 Cr | 0.00 Cr | 0.00 Cr | 192.97 Cr | 253.49 Cr | 60.52 Cr | 0.00 Cr | 192.97 Cr |
| 2023-06-30 | 486.87 Cr | 174.71 Cr | 0.00 Cr | 0.00 Cr | 174.71 Cr | 479.53 Cr | 304.82 Cr | 0.00 Cr | 174.71 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,619,911,900.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Whole-Time Director & Executive Chairman
Mr. Ramesh C. Juneja
Gender: male
Year Born: 1955
Chief Financial Officer
Mr. Ashutosh Dhawan MBA
Gender: male
Year Born: 1968
Director Finance, Human Resources & Admin
Mr. Prem Kumar Arora
Gender: male
Year Born: 1947
Chief Scientific Officer (Research Centre)
Dr. Anil Kumar
Gender: Not Specified
Year Born: 1953
Whole-Time Director
Mr. Satish Kumar Sharma
Gender: male
Year Born: 1973
Vice Chairman & MD
Mr. Rajeev Juneja
Gender: male
Year Born: 1965
Chief Operating Officer
Mr. Arjun Juneja
Gender: male
Year Born: 1986
Chief Executive Officer & Whole-Time Director
Mr. Sheetal Arora
Gender: male
Year Born: 1975
Senior President & Group Chief Information Officer
Mr. Pramod Gokhale
Gender: male
Year Born: 1970
Director of Technology
Mr. Chanakya Juneja
Gender: male
Year Born:
FAQs about Mankind Pharma Limited
Who is the CEO of the company?
The CEO is Mr. Sheetal Arora.
What is the current market price of the stock?
The current price is ₹2,588.40.
What is the 52-week price range?
The range is ₹1901.05-3054.8.
What is the market capitalization of the company?
The market capitalization is ₹106,791.82 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 51.02.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Mankind Pharma Limited (ISIN: INE634S01028) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹106,791.82 crores and an average daily volume of 635,117 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.